Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Depreciation & Amortization (CF) (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $402000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 11.45% to $402000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 8.52% decrease, with the full-year FY2024 number at $1.8 million, up 2.83% from a year prior.
  • Depreciation & Amortization (CF) was $402000.0 for Q3 2025 at Werewolf Therapeutics, down from $406000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $464000.0 in Q1 2024 to a low of $39000.0 in Q1 2021.
  • A 5-year average of $322736.8 and a median of $417000.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 768.75% in 2022, then decreased 11.45% in 2025.
  • Werewolf Therapeutics' Depreciation & Amortization (CF) stood at $48000.0 in 2021, then skyrocketed by 768.75% to $417000.0 in 2022, then grew by 10.31% to $460000.0 in 2023, then decreased by 3.91% to $442000.0 in 2024, then fell by 9.05% to $402000.0 in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Depreciation & Amortization (CF) are $402000.0 (Q3 2025), $406000.0 (Q2 2025), and $426000.0 (Q1 2025).